Gavi has welcomed a recommendation to include Ervebo, the current Ebola vaccine, in clinical trials for Bundibugyo virus disease. The World Health Organization's recommendation is based on available data on Ervebo's safety and immunogenicity. This vaccine has contributed to containing several Ebola outbreaks in the past.

As a result, it may be introduced directly into phase 3 evaluations for Bundibugyo virus disease. Doses of Ervebo from the global emergency stockpile of Ebola vaccines may be used in the trials. For more information on the potential use of Ervebo in clinical trials, further details are available from the source.